| Literature DB >> 31196459 |
Márcio G Kiuchi1, Murray D Esler2, Gregory D Fink3, John W Osborn4, Christopher T Banek4, Michael Böhm5, Kate M Denton6, Gerald F DiBona7, Thomas H Everett8, Guido Grassi9, Richard E Katholi10, Mark M Knuepfer11, Ulla C Kopp12, David J Lefer13, Thomas E Lohmeier14, Clive N May15, Felix Mahfoud5, Julian F R Paton16, Roland E Schmieder17, Peter R Pellegrino18, Yehonatan Sharabi19, Markus P Schlaich20.
Abstract
Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.Entities:
Keywords: blood pressure; cardiovascular disease; hypertension; renal denervation; sympathetic nervous system
Mesh:
Year: 2019 PMID: 31196459 DOI: 10.1016/j.jacc.2019.04.015
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094